In a previous blog post, I discussed what reporters look for when they dig into the data from the various COVID-19 vaccine clinical trials. That post covered the do’s, but it didn’t cover the red flags that reporters should watch for as well.
Vinay Prasad, M.D., a hematologist-oncologist and associate professor of medicine at the University of California, San Francisco, followed up his Twitter thread on what to look for with a list of common problems in vaccine clinical trials that journalists also should monitor: Continue reading
You may have read reports about a new blood test to detect early brain changes that can flag common markers of Alzheimer’s disease. It’s moved one step closer to clinical use and could be a game-changer, according to researchers.
Up to two decades before people develop the characteristic memory loss and confusion of Alzheimer’s disease, damaging clumps of protein start to build up in their brains. Continue reading
There’s no doubt that a diagnosis of Alzheimer’s disease is devastating for both the person who receives it and for their family.
Although it’s the sixth leading cause of death in the U.S., affecting nearly 6 million people, finding a cure or even a long-term treatment has proven elusive. Most drugs never make it out of Phase I or II trials. Continue reading
Most often, reporting on medical studies means recounting numbers, demographic details, findings and statistical probability values that are so abstract that it’s easy to forget they all refer to actual people enrolled in the study. With epidemiological studies, the researchers themselves often never meet the people they report on, especially if it’s a retrospective study that primarily relies on electronic medical records.
But clinical trials are a different story. Continue reading
You may have recently heard about the multimillion-dollar donation that Bill Gates and Leonard Lauder made to support research into biomarkers for early detection of Alzheimer’s disease and related dementias.
The Diagnostics Accelerator initiative is part of the Alzheimer’s Drug Discovery Foundation’s (ADDF) effort to speed diagnosis and develop drugs that can prevent, treat, and cure the disease. Lauder was an ADDF co-founder. Continue reading